Clinical Trial Results Show Active Chest Tube Clearance as Part of an ERAS Program Significantly Improves Outcomes in Cardiac Surgery
IRVINE, Calif.--(BUSINESS WIRE)--ClearFlow, Inc., a medical device company based in Irvine, California, announced positive results from a clinical trial published in the peer-reviewed journal Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. The study, conducted by cardiac surgeons at Franciscan Health Indianapolis, is detailed in the article, ' Active Chest Tube Clearance Added to an Enhanced Recovery After Cardiac Surgery (ERAS) Program Improves Outcomes and Reduces Resource Utilization. '
The prospective trial evaluated ClearFlow's PleuraFlow Active Clearance Technology (ACT) System, which significantly reduced retained blood complications in heart surgery patients. The system minimized chest tube clogging, lowered the incidence of retained blood syndrome (RBS) and postoperative atrial fibrillation (POAF), as well as reduced median ICU hours during recovery.
The PleuraFlow System, used at the bedside in the ICU, enables clinicians to maintain chest tube patency without compromising the sterile field. By ensuring effective evacuation of blood and fluid from the surgical site postoperatively, PleuraFlow reduces retained blood, a known contributor to complications such as POAF, pleural effusions, and pericardial effusions.
Conducted from January 2020 to August 2023 at Franciscan Health Indianapolis, this pragmatic, prospective observational study included 1,334 adult cardiac surgery patients. The control group (650 patients) received standard drainage, while the intervention group (684 patients) received PleuraFlow's Active Tube Clearance. Key findings demonstrated for the patients receiving Active Tube Clearance include:
41% reduction in RBS (8.2% vs. 4.8%, p=0.014)
17% decrease in POAF (33.8% vs. 28.1%, p=0.049)
30% reduction in median ICU hours (51.6 vs. 36.3 hours, p<0.001)
64% reduction in ICU readmissions (3.2% vs. 1.17%, p=0.013)
23% decrease in total chest drainage (p<0.001), enabling earlier chest tube removal and faster recovery
Principal investigator Marc Gerdisch, MD, Chief of Cardiovascular and Thoracic Surgery and Co-Director of the Heart Valve Center at Franciscan Health, stated, 'We studied the clinical outcomes and financial implications of PleuraFlow chest drains when added to our established ERAS Cardiac program protocols. The unequivocal positive results have led to significantly fewer complications, and hospital days. More recently, we have leveraged our confidence the chest is well drained to achieve a median time to extubation of zero hours. Perhaps most importantly, the bedside nurse is able to ensure the chest drain is patent.'
Louis Perrault, MD, PhD, a study coauthor and cardiac surgeon at the Montreal Heart Institute, added, 'Conventional chest tubes are prone to clogging, which can hinder recovery. This study, alongside prior research, strongly supports incorporating PleuraFlow's active clearance into ERAS Cardiac Surgery programs to reduce RBS, POAF, and ICU time.'
'This study strengthens the evidence for PleuraFlow's role in improving patient outcomes,' said Hannah Beathard, CEO of ClearFlow. 'By maintaining chest tube patency, PleuraFlow reduces retained blood and related complications, aligning with the ERAS Cardiac Society's Class I, Level B-NR recommendation for active chest tube maintenance as a critical component of optimal cardiac surgery recovery.'
About ClearFlow, Inc.
ClearFlow, Inc. is an Irvine, CA based medical device company that has developed a patented active blood and fluid evacuation system to speed recovery, reduce complications and lower healthcare costs related to medical tube obstruction. The company has been awarded several prestigious awards, including the Global Frost & Sullivan Award for New Product Innovation, the European Association of Cardiothoracic Surgeons Techno-College Innovation Award for worldwide innovation that has the potential to change the standard of care in heart and lung surgery, and the Innovations in Cardiovascular Interventions Award, among others.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Why Oscar Health, Inc. (OSCR) Soared On Thursday
We recently published a list of . In this article, we are going to take a look at where Oscar Health, Inc. (NYSE:OSCR) stands against other best-performing stocks on Thursday. Oscar Health snapped a five-day losing streak on Thursday, jumping 10.6 percent to close at $15.65 apiece as investors resorted to bargain-hunting while waiting for more concrete developments on the Trump administration's Medicare Advantage review. Earlier this year, lawmakers passed a $5-trillion tax-and-spending package that shaves as much as $900 billion in Medicaid, which servers over 70 million low-income households. A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. Now, Senate Republicans to broaden savings by looking for supposed inefficiencies in the Medicare program for senior citizens. In the first quarter of the year, Oscar Health, Inc. (NYSE:OSCR) registered a 55-percent increase in attributable net income of $275 million versus the $177 million registered in the same period last year. Revenues rose by 42 percent to $3.046 billion from $2.142 billion year-on-year. Overall, OSCR ranks 5th on our list of best-performing stocks on Thursday. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
19 hours ago
- Yahoo
Uptick in tick bites reported in Central Pennsylvania emergency rooms
JOHNSTOWN, Pa. (WTAJ) — With summer temperatures reaching Central Pennsylvania, emergency rooms are noticing an uptick in ticks. 'The seasons are now changing and so we're doing a lot more outdoor stuff,' said Nsikak Daniel, M.D., an emergency room physician at Conemaugh Memorial Medical Center in Johnstown. 'Ticks are just one of those things you kind of get when you go out into the woods.' While children and older adults may have the most adverse reactions to tick bites, everyone should take precautions. Juniata College receives approval from state nursing board for new nursing program 'Wear clothing that covers you up, you know, socks and stuff like that with your shoes. Insect repellents sometimes can help,' Daniels said. Lyme Disease is a common illness carried by ticks, often characterized by a bullseye–shaped rash around a bite. While it's become more prevalent, Daniels said it's not the only thing you should worry about. 'One of the complications a lot of people don't think about is something that's called anaplasmosis. It's a very serious, tick borne illness and it's something that can affect your bloodstream. It can affect your organs and cause organ damage,' Daniels said. If you get bit and have any concerns that you did not remove the tick or notice signs of infection such as fever or a rash, you should go to the emergency room immediately. Veterinarians also said they're seeing a rise in bites and infections in dogs. They said the best way to keep your furry friend safe is to use medications and repellents, mow your lawn and avoid high risk areas like tall grass and wooded areas during tick season. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
